首页 > R&D Systems > R&D Systems/Recombinant Human IL-6 Protein/206-IL-050/CF/50 ug

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

R&D Systems/Recombinant Human IL-6 Protein/206-IL-050/CF/50 ug

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

206-IL-050/CF-50ug

品牌：

R&D Systems

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Purity>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.Endotoxin LevelActivityMeasured in a cell proliferation assay using T1165.85.2.1 mouse plasmacytoma cells. Nordan, R.P. et al. (1987) J. Immunol. 139:813. The ED50 for this effect is 0.2-0.8 ng/mL.The specific activity of Recombinant Human IL-6 is approximately 1.1 x 105 IU/μg, which is calibrated against human IL‑6 WHO International Standard (NIBSC code: 89/548).SourceE. coli-derived Pro29-Met212Accession #Q75MH2 N-terminal Sequence AnalysisPro29Predicted Molecular Mass20.3 kDa References:Mansell, A. and B.J. Jenkins (2013) Cytokine Growth Factor Rev. 24:249.Schuett, H. et al. (2009) Thromb. Haemost. 102:215.Erta, M. et al. (2012) Int. J. Biol. Sci. 8:1254.Garbers, C. et al. (2012) Cytokine Growth Factor Rev. 23:85.Mihara, M. et al. (2012) Clin. Sci. (Lond.) 122:143.Hirano, T. et al. (1986) Nature 324:73.Kestler, D.P. et al. (1995) Blood 86:4559.Kestler, D.P. et al. (1999) Am. J. Hematol. 61:169.Bihl, M.P. et al. (2002) Am. J. Respir. Cell Mol. Biol. 27:48.Alberti, L. et al. (2005) Cancer Res. 65:2.Murakami, M. et al. (1993) Science 260:1808.Muller-Newen, G. (2003) Sci. STKE 2003:PE40.Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.Cerutti, A. et al. (1998) J. Immunol. 160:2145.Long Name:Interleukin 6Entrez Gene IDs:3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 100034196 (Equine); 493687 (Feline); 100008733 (Rabbit)Alternate Names:B cell stimulatory factor-2; B-cell differentiation factor; BSF-2; BSF2CTL differentiation factor; CDF; HGFHSFIFNB2Hybridoma growth factor; IFN-beta-2; IL6; IL-6; IL-6B-cell stimulatory factor 2; Interferon beta-2; interleukin 6 (interferon, beta 2); interleukin BSF-2; interleukin-6; MGI-2ABackground:Interleukin-6 (IL-6) is a pleiotropic,alpha -helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression (1-5). Mature human IL-6 is 183 amino acids (aa) in length and shares 39% aa sequence identity with mouse and rat IL-6 (6). Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (7-10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alphaassociation with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R alphaare generated by both alternative splicing and proteolytic cleavage (5). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alphaelicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha(5). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alphais predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 5). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alphabut not from other cytokines that use gp130 as a co-receptor (5, 13). IL-6, along with TNF-alphaand IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis (1, 2, 5). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells (1, 14).

R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。